Should I Buy TCMD? TCMD 2026 Analysis

Should You Buy Tactile Systems Technology Inc (TCMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

28.580

1 Day change

-0.17%

52 Week Range

31.380

Analysis Updated At

2026/01/26

Tactile Systems Technology Inc (TCMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has shown strong financial growth in Q3 2025, with significant YoY increases in revenue, net income, and EPS. Analysts have upgraded the stock with higher price targets, citing a turnaround in the business and expected double-digit growth in FY26. While technical indicators are mixed, the stock's valuation and growth potential make it a favorable investment opportunity.

Technical Analysis

The stock's MACD is negative and expanding, indicating bearish momentum. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the RSI is neutral at 32.155. The stock is trading near its support level (S1: 28.889), suggesting limited downside risk.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have upgraded the stock with higher price targets, citing strong financial performance and a turnaround in the business.
The company has shown significant YoY growth in revenue, net income, and EPS in Q3
AffloVest business continues to outperform expectations, and the lymphedema business has stabilized.

Neutral/Negative Catalysts

MACD indicates bearish momentum, which could signal short-term price weakness.
Options data shows a high put-call volume ratio (4.94), suggesting bearish sentiment among options traders.

Financial Performance

In Q3 2025, Tactile Systems reported revenue of $85.76M (+17.32% YoY), net income of $8.21M (+59.24% YoY), and EPS of $0.36 (+71.43% YoY). Gross margin improved to 75.1% (+1.36% YoY), indicating strong operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on TCMD. Piper Sandler upgraded the stock to Overweight with a price target of $35, citing stabilization in the lymphedema business and growth potential in AffloVest. Lake Street raised its price target to $32 after a strong Q3 performance. BTIG upgraded the stock to Buy, highlighting the company's turnaround and improved performance.

4 Analyst Rating

Wall Street analysts forecast TCMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCMD is 31.67 USD with a low forecast of 28 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 28.630

Low

Averages

31.67

High

Current: 28.630

Low

Averages

31.67

High

Piper Sandler

Adam Maeder

Neutral -> Overweight

upgrade

$20 -> $35

AI Analysis

2026-01-05

Reason

Piper Sandler

Adam Maeder

Price Target

$20 -> $35

AI Analysis

2026-01-05

upgrade

Neutral -> Overweight

Reason

Piper Sandler analyst Adam Maeder upgraded Tactile Systems to Overweight from Neutral with a price target of $35, up from $20.

Piper Sandler

Adam Maeder

Neutral -> Overweight

upgrade

$20 -> $35

2026-01-05

Reason

Piper Sandler

Adam Maeder

Price Target

$20 -> $35

2026-01-05

upgrade

Neutral -> Overweight

Reason

As previously reported, Piper Sandler analyst Adam Maeder upgraded Tactile Systems to Overweight from Neutral with a price target of $35, up from $20. The firm notes the lymphedema business appears to have stabilized and has a couple of catalysts on-the-come; Afflovest has consistently outperformed expectations in 2025 year-to-date and it sees plenty of growth runway going forward; valuation screens positive despite the run in the stock over the past 6 months; and Piper thought management gave a bullish update at the 2025 Piper Sandler Healthcare Conference. Looking ahead, the firm sees a potential pathway back to double-digit growth in FY26 and beyond. Piper combines this level of expected top-line growth with net income profitability, and it sees a favorable risk-reward.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TCMD

Unlock Now

TCMD Should I Buy

TCMD Should I Buy

Should You Buy Tactile Systems Technology Inc (TCMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch